Recent changes
Jump to navigation
Jump to search
Track the most recent changes to the wiki on this page.
List of abbreviations:
- N
- This edit created a new page (also see list of new pages)
- m
- This is a minor edit
- b
- This edit was performed by a bot
- (±123)
- The page size changed by this number of bytes
23 May 2024
|
N 14:51 | Glofitamab-gxbm 2 changes history +8,803 [Muhammad Waleed (2×)] | |||
|
14:51 (cur | prev) +6,189 Muhammad Waleed talk contribs | ||||
N |
|
14:40 (cur | prev) +2,614 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=glofitamab. |aOrAn=a |drugClass=bispecific antibodies |indicationType=treatment |indication=COLUMVI (glofitamab) has been approved by the FDA for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified (NOS), or large B-cell lymphoma arising from follicular lymphoma aft...") |
|
N 14:22 | Rozanolixizumab-noli 2 changes history +8,759 [Muhammad Waleed (2×)] | |||
|
14:22 (cur | prev) +5,524 Muhammad Waleed talk contribs | ||||
N |
|
12:43 (cur | prev) +3,235 Muhammad Waleed talk contribs (Created page with "{{DrugProjectFormSinglePage |authorTag=Muhammad Waleed, M.B.B.S. [mailto:muhammad_waleed@ymail.com] |genericName=Rozanolixizumab-noli (Rystiggo) |aOrAn=a |drugClass=Neonatal Fc receptor blocker |indicationType=treatment |indication=Rystiggo is indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive. |adverseReac...") |
|
m 07:03 | Non-degenerate nucleotides per response element 2 changes history −98 [Marshallsumter (2×)] | |||
m |
|
07:03 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) | |||
m |
|
07:01 (cur | prev) −49 Marshallsumter talk contribs (→Tabulation of counts) |
04:38 | Pegunigalsidase alfa-iwxj diffhist +1,255 Alen Antony talk contribs |